Gender-affirming hormone therapy and migraine: A brief evidence summary and proposal for a new diagnostic entity for ICHD-4

Cephalalgia Reports · Published 2026-07-01 · DOI 10.1177/25158163261472312

Free full text

Authors (2)

Karen dos Santos Ferreira, Ana Miriam Velly

Abstract

DOAJ holds no abstract for this record.

Read the article at the publisher →

Publication details

Year

2026

Citation

Ferreira, K., Velly, A. (2026). Gender-affirming hormone therapy and migraine: A brief evidence summary and proposal for a new diagnostic entity for ICHD-4. Cephalalgia Reports. https://doi.org/10.1177/25158163261472312

Related articles

• A randomized controlled trial on combining therapeutic patient education with standard care versus standard care alone for chronic migraine: Effects on patient-reported outcome measures · Cephalalgia Reports · 2025 · Same journal
• Digital screen exposure, lifestyle behaviors, and headache complaints among healthcare students: A multinational study from the MENA region · Cephalalgia Reports · 2026 · Same journal
• Migraine care in the MENA region, a focus on North Africa · Cephalalgia Reports · 2025 · Same journal
• Sex differences in cluster headache, treatment insights, and burden of disease in Türkiye: A multi-center cross-sectional study · Cephalalgia Reports · 2026 · Same journal
• Migraine care in the Eastern Europe region · Cephalalgia Reports · 2026 · Same journal
• Prospective observational study of three-month response to eCOT-NS device in patients with headache · Cephalalgia Reports · 2025 · Same journal
• Effectiveness and predictors of response to intravenous dihydroergotamine in the treatment of primary headache disorders: A service evaluation · Cephalalgia Reports · 2026 · Same journal
• Perineural botulinum toxin in the treatment of trigeminal traumatic neuropathic pain · Cephalalgia Reports · 2026 · Same journal
• Revealing the immune face: TIM3 as a window into T-cell immunity in migraine? – A retrospective cohort study · Cephalalgia Reports · 2026 · Same journal
• Patient-reported outcomes from a real-world evidence study in individuals with migraine initiating eptinezumab after ≥1 prior calcitonin gene-related peptide (CGRP)-targeted preventive therapy · Cephalalgia Reports · 2026 · Same journal